In Vivo and in Vitro Regulatory Effect of Silibinin on Some Metabolic Enzyme Activities against Cobalt Induced Toxicity in Rats: A Biochemical Approach.

The study aimed to examine the in vivo inhibition effect of cobalt ion and silibinin on metabolic enzymes such as glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (6PGD), glutathione reductase (GR), and glutathione S-transferase (GST) and their in vitro inhibition effect on 6PGD. Twenty-four Wistar Albino rats weighing approximately 250-300 g were used in the study. The rats were divided into 4 groups as group 1 (control): isotonic serum (0.5 mL i.p), group 2 (cobalt): (150 mg kg/day cobalt), group 3 (silibinin): (100 mg/kg/day silibinin), group 4 (cobalt + silibinin). As a result of the in vivo applications, a statistically significant decrease was observed in the activities of G6PD (p < 0.05), 6PGD (p < 0.05), GR (p < 0.05), and GST (p < 0.05) enzymes in the groups that were administered cobalt compared to the control group. It was also found that the activities of G6PD (p < 0.05), 6PGD (p > 0.05), GR (p > 0.05), and GST (p > 0.05) enzymes increased in groups that were administered cobalt + silibinin compared to the group that was administered cobalt. As for in vitro applications, it was found that different Co2+ ions inhibited 6PGD enzyme which was obtained as a result of purification with IC50 = 346.6 µM value, while silibinin increased 6PGD enzyme activity within the concentration range of 100-750 µM by 40%. As a result, it was found that cobalt ions had an inhibition effect on G6PD, GR, and GST enzymes, which are vitally important for living metabolism, in vitro and in vivo and inhibited 6PGD enzyme activity in vitro, and silibinin increased these enzyme activities in vivo and 6PGD enzyme activity both in vivo and in vitro and decreased the inhibition effect.

The Effects of Sodium Tetraborate against Lead Toxicity in Rats: The Behavior of Some Metabolic Enzymes.

This study was planned to research the in vivo effects of lead (Pb) ions and sodium tetraborate (Na2B4O7) on G6PD and 6PGD, which are some of the enzymes of the pentose phosphate pathway, which carries vital importance for metabolism, and GR and GST, which are glutathione metabolism enzymes, and the in vitro effects of the same agents on the 6PGD enzyme. According to the in vivo analysis results, in comparison to the control group, the rat liver G6PD (p < 0.05), and 6PGD (p < 0.01) enzyme activities in the Na2B4O7 group were significantly lower. In addition, GR and GST enzyme activities were insignificantly lower in the Na2B4O7 group compared to the control group (p > 0.05). The Pb group had lower G6PD and 6PGD enzyme activity levels and higher GR and GST enzyme activity levels compared to the control group, while these changes did not reach statistical significance (p > 0.05). In the in vitro analyses of the effects of Pb ions on the 6PGD enzyme that was purified out of rat liver with the 2',5'-ADP-Sepharose 4B affinity chromatography method, it was determined that Pb ions (200-1200 µM) increased the rat liver 6PGD enzyme activity levels by 33%. On the other hand Na2B4O7 was not significantly effective on 6PGD activity. These results will also contribute to future studies in understanding the physiopathology of the states triggered by Pb ions and sodium tetraborate (Na2B4O7).

The effect of astaxanthin and cadmium on rat erythrocyte G6PD, 6PGD, GR, and TrxR enzymes activities in vivo and on rat erythrocyte 6PGD enzyme activity in vitro.

In this study, the effects of astaxanthin (AST) that belongs to carotenoid family and cadmium (Cd), which is an important heavy metal, on rat erythrocyte G6PD, 6PGD, GR, and TrxR enzyme activities in vivo and on rat erythrocyte 6PGD enzyme activity in vitro were studied. In in vitro studies, 6PGD enzyme was purified from rat erythrocytes with 2',5'-ADP Sepharose4B affinity chromatography. Results showed inhibition of enzyme by Cd at IC50 ; 346.5 µM value and increase of 6PGD enzyme activity by AST. In vivo studies showed an increase in G6PD, 6PGD, and GR enzyme activities (P Ëƒ 0.05) and no chance in TrxR enzyme activity by AST. Cd ion inhibited G6PD, 6PGD, and GR enzyme activities (P Ë‚ 0.05) and also decreased TrxR enzyme activity (P Ëƒ 0.05). AST + Cd group G6PD enzyme activity was statistically low compared with control group (P Ë‚ 0.05). 6PGD and TrxR enzyme activities decreased without statistical significance (P Ëƒ 0.05); however, GR enzyme activity increased statistically significantly (P Ë‚ 0.05).

Serum endocan level and the severity of spinal cord injury.

OBJECTIVE: To determine whether the endocan level may be related to the severity of spinal cord injury. BACKGROUND: Several biomarkers were evaluated for this purpose, but endocan has never been studied before. It is correlated to endothelial dysfunction and ischemia, which are the characteristics of spinal cord injury in most cases. MATERIAL AND METHODS: A total of 21 male Sprague-Dawley rats weighing 300-350 g were randomly divided into three groups. In Group I, only a laminectomy was performed; in Group II, a mild SCI was performed after laminectomy; and, in Group III, a severe SCI was performed after laminectomy. At 48 h after the injury, after neurological assessment by Tarlov method, all animals were euthanized. A 5 cc blood sample was drawn for biochemical analysis, and spinal cord tissues were removed for histopathological examination. RESULTS: The difference between Groups I and III was statistically significant (p < 0.05). There was also a moderately positive correlation between the severity of SCI and the endocan level (r = 0.59, p < 0.05). CONCLUSION: The endocan level may be used as an indicator to determine prognosis after SCI (Tab. 1, Fig. 2, Ref. 24). Text in PDF www.elis.sk.

Natural Inhibitors and Lipids in Patients with Sickle Cell Disease.

Microvascular occlusion in sickle cell disease (SCD) is a multifactorial process. Disordered coagulation may play a role in the pathogenesis of vaso occlusive crisis (VOC). The aim of this study was to evaluate the patients and to investigate their Protein C (PC), Protein S (PS) and AT-III levels during normal and crisis periods. A total of 18 patients with SCD were included in this study at the Antalya State Hospital, Thalassemia Center. The mean number of VOC episodes of the patients per year was 4.1 - 3.2. Complications in patients included 4 cases of osteonecrosis (23.5%), 2 cases of holealithiasis (11.7%), 2 cases of leg ulcers (11.7%), and 3 splenectomies (17.6%). The patients during noncrisis periods have lower cholesterol and higher triglycerides levels than the controls (p< 0.001). Hepatic and renal functions were normal in all patients. The mean totals of the PS, PC and AT-III levels were statistically lower both in non crisis and in crisis periods than the control (p< 0.001), but there was no statistical difference between the levels durining noncrisis and crisis periods. In conclusion, PC, PS and AT-IIII deficiencies in patients with SCD are certain. However, these deficiencies do not change during noncrisis and crisis situations and does not play a role on the period of crisis. Abnormal lipid patterns may be a predisposing condition for a crisis.